SEB repeats its Buy rating on pharmaceutical company Genmab and raises the price target to DKK 3,000 from DKK 2,775 following strong study data for Epkinly in combination with R-CHOP.
The results exceeded the bank’s optimistic scenario and showed a PFS hazard ratio of 0.49. SEB sees potential for broad use as a first-line treatment for DLBCL and raises its estimates for peak sales.
Finwire reported yesterday that SEB had raised the price target to DKK 2,775 – this is not correct.
